Cilcare
Created in 2014
- BETA
Trend leader (A+)
Existing signals make this entity one of the most dynamic startups Social networks
265 4,693Activities
Technologies
Entity types
Location
Rue du Professeur Joseph Anglada, 34090 Montpellier, France
Montpellier
France
Employees
Scale: 11-50
Estimated: 43
SIREN
803146125Engaged corporates
43
12 39Added in Motherbase
5 years, 7 months ago
biotech Value proposition
MAKING HEARING A PRIORITY
CILCARE is a biotech dedicated to harnessing auditory sciences to reshape the future of care via early diagnosis and targeted treatment. We believe hearing acts as a valuable indicator of our health and must be monitored and preserved accordingly. As awareness of the link between hearing and chronic health conditions grows, auditory sciences are paving the way for the early detection of chronic neurocognitive, inflammatory, and age-related diseases.
CILCARE External Innovation supports its partners in the health and life-sciences sector in the development of new therapies to prevent and treat auditory-related diseases including inherited hearing loss, synaptopathy, ototoxicity, sensorineural hearing loss and tinnitus.
CILCARE Therapeutics has forged a portfolio of proprietary drug candidates and co-developed programs, while pioneering an unprecedented clinical approach to developing compounds targeting cochlear synaptopathy.
CILCARE Auditory Analytics aims to position hearing as a key asset of preventive medicine and global healthcare monitoring.
We aim to utilize patients' auditory measurements to define digital auditory signatures that will serve to characterize different forms of hearing impairments or other pathologies with precision.
hearing disorders, tinnitus, hearing loss, pharmaceutical development, pharmacology, clinical development, preclinical development, GLP ototoxicology, hearing loss, tinnitus, auditory safety, ear disorders, AI, and precision medicineOriginal language
MAKING HEARING A PRIORITY
CILCARE is a biotech dedicated to harnessing auditory sciences to reshape the future of care via early diagnosis and targeted treatment. We believe hearing acts as a valuable indicator of our health and must be monitored and preserved accordingly. As awareness of the link between hearing and chronic health conditions grows, auditory sciences are paving the way for the early detection of chronic neurocognitive, inflammatory, and age-related diseases.
CILCARE External Innovation supports its partners in the health and life-sciences sector in the development of new therapies to prevent and treat auditory-related diseases including inherited hearing loss, synaptopathy, ototoxicity, sensorineural hearing loss and tinnitus.
CILCARE Therapeutics has forged a portfolio of proprietary drug candidates and co-developed programs, while pioneering an unprecedented clinical approach to developing compounds targeting cochlear synaptopathy.
CILCARE Auditory Analytics aims to position hearing as a key asset of preventive medicine and global healthcare monitoring.
We aim to utilize patients' auditory measurements to define digital auditory signatures that will serve to characterize different forms of hearing impairments or other pathologies with precision.
Accueil - Cilcare
https://www.cilcare.com/
| Corporate | Type | Tweets | Articles | |
|---|---|---|---|---|
 Veolia Energy, Environmental Services | Veolia Energy, Environmental Services | Other 4 Nov 2024 | | |
 Mouvement Impact France Civic and Social Organizations | Mouvement Impact France Civic and Social Organizations | Other 5 Oct 2024 | | |
 Pfizer Pharmaceutical, Pharmaceutical Manufacturing | Pfizer Pharmaceutical, Pharmaceutical Manufacturing | Other 5 Oct 2024 | | |
 Servier Pharmaceuticals Pharmaceutical, Pharmaceutical Manufacturing | Servier Pharmaceuticals Pharmaceutical, Pharmaceutical Manufacturing | Other 5 Oct 2024 | | |
 MEDEF NGO, Think Tank, Civic and Social Organizations | MEDEF NGO, Think Tank, Civic and Social Organizations | Other 15 Sep 2024 | | |
 J.P. Morgan Bank | J.P. Morgan Bank | Other 5 Mar 2024 | | |
 Shionogi & Co., Ltd Pharmaceutical | Shionogi & Co., Ltd Pharmaceutical | Other 5 Oct 2024 | | |
 | The Exploration Company | Other 14 Nov 2023 | | |
 Moderna Pharmaceutical, Biotechnology, Biotechnology Research | Moderna Pharmaceutical, Biotechnology, Biotechnology Research | Other 25 Apr 2024 | | |
 Takeda Pharmaceutical, Pharmaceutical Manufacturing | Takeda Pharmaceutical, Pharmaceutical Manufacturing | Other 25 Apr 2024 | | |